Cargando…

Clinical experience with N-carbamylglutamate in a single-centre cohort of patients with propionic and methylmalonic aciduria

BACKGROUND: The effect of long-term N-carbamylglutamate (NCG) treatment on the rate and severity of decompensations due to propionic aciduria (PA) and methylmalonic aciduria (MMA) is unknown. This paper presents clinical experience from a single-centre cohort of patients with PA and MMA who received...

Descripción completa

Detalles Bibliográficos
Autores principales: Burlina, Alberto, Cazzorla, Chiara, Zanonato, Elisa, Viggiano, Emanuela, Fasan, Ilaria, Polo, Giulia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949587/
https://www.ncbi.nlm.nih.gov/pubmed/27489777
http://dx.doi.org/10.1016/j.ymgmr.2016.06.007
_version_ 1782443457639350272
author Burlina, Alberto
Cazzorla, Chiara
Zanonato, Elisa
Viggiano, Emanuela
Fasan, Ilaria
Polo, Giulia
author_facet Burlina, Alberto
Cazzorla, Chiara
Zanonato, Elisa
Viggiano, Emanuela
Fasan, Ilaria
Polo, Giulia
author_sort Burlina, Alberto
collection PubMed
description BACKGROUND: The effect of long-term N-carbamylglutamate (NCG) treatment on the rate and severity of decompensations due to propionic aciduria (PA) and methylmalonic aciduria (MMA) is unknown. This paper presents clinical experience from a single-centre cohort of patients with PA and MMA who received continuous long-term treatment with NCG. METHODS: The effect of oral NCG treatment (initial dose: 50 mg/kg/day) was investigated in patients with PA or MMA who were experiencing frequent progressive episodes of metabolic decompensation, who had pathological levels of ammonia, and who were referred to the Division of Metabolic Diseases, University Hospital of Padova between August 2014 and December 2015. Clinical and biochemical data, including the number of metabolic decompensations, lactic acid, uric acid and plasma ammonia levels, protein intake and body weight, were collected before and after the initiation of NCG treatment. RESULTS: Eight patients with PA (n = 4) and MMA (n = 4) aged 2–20 years were treated with NCG (50 mg/kg/day) for 7–16 months. Metabolic decompensation episodes decreased in number and severity, with three of the patients having no episodes (pre-treatment: 24 episodes; post-treatment: 9 episodes). After NCG treatment, all episodes were treated at home and none required hospitalisation, lactic acid values were 1.3–2.1 mmol/L and uric acid values were 0.21–0.36 mmol/L. Significant reductions in blood ammonia levels after NCG initiation were observed in five patients, whereas levels were reduced or maintained in the normal range in the remainder. Over the treatment period, patients had an increase in natural protein intake of 20–50% and gained 0–6.5 kg in bodyweight. CONCLUSION: These observations suggest that, in addition to short-term benefits for the acute treatment of hyperammonaemia, NCG may be effective and well tolerated as a long-term treatment in patients with severe PA and MMA, and that further prospective studies are warranted.
format Online
Article
Text
id pubmed-4949587
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-49495872016-08-03 Clinical experience with N-carbamylglutamate in a single-centre cohort of patients with propionic and methylmalonic aciduria Burlina, Alberto Cazzorla, Chiara Zanonato, Elisa Viggiano, Emanuela Fasan, Ilaria Polo, Giulia Mol Genet Metab Rep Research Paper BACKGROUND: The effect of long-term N-carbamylglutamate (NCG) treatment on the rate and severity of decompensations due to propionic aciduria (PA) and methylmalonic aciduria (MMA) is unknown. This paper presents clinical experience from a single-centre cohort of patients with PA and MMA who received continuous long-term treatment with NCG. METHODS: The effect of oral NCG treatment (initial dose: 50 mg/kg/day) was investigated in patients with PA or MMA who were experiencing frequent progressive episodes of metabolic decompensation, who had pathological levels of ammonia, and who were referred to the Division of Metabolic Diseases, University Hospital of Padova between August 2014 and December 2015. Clinical and biochemical data, including the number of metabolic decompensations, lactic acid, uric acid and plasma ammonia levels, protein intake and body weight, were collected before and after the initiation of NCG treatment. RESULTS: Eight patients with PA (n = 4) and MMA (n = 4) aged 2–20 years were treated with NCG (50 mg/kg/day) for 7–16 months. Metabolic decompensation episodes decreased in number and severity, with three of the patients having no episodes (pre-treatment: 24 episodes; post-treatment: 9 episodes). After NCG treatment, all episodes were treated at home and none required hospitalisation, lactic acid values were 1.3–2.1 mmol/L and uric acid values were 0.21–0.36 mmol/L. Significant reductions in blood ammonia levels after NCG initiation were observed in five patients, whereas levels were reduced or maintained in the normal range in the remainder. Over the treatment period, patients had an increase in natural protein intake of 20–50% and gained 0–6.5 kg in bodyweight. CONCLUSION: These observations suggest that, in addition to short-term benefits for the acute treatment of hyperammonaemia, NCG may be effective and well tolerated as a long-term treatment in patients with severe PA and MMA, and that further prospective studies are warranted. Elsevier 2016-07-13 /pmc/articles/PMC4949587/ /pubmed/27489777 http://dx.doi.org/10.1016/j.ymgmr.2016.06.007 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Burlina, Alberto
Cazzorla, Chiara
Zanonato, Elisa
Viggiano, Emanuela
Fasan, Ilaria
Polo, Giulia
Clinical experience with N-carbamylglutamate in a single-centre cohort of patients with propionic and methylmalonic aciduria
title Clinical experience with N-carbamylglutamate in a single-centre cohort of patients with propionic and methylmalonic aciduria
title_full Clinical experience with N-carbamylglutamate in a single-centre cohort of patients with propionic and methylmalonic aciduria
title_fullStr Clinical experience with N-carbamylglutamate in a single-centre cohort of patients with propionic and methylmalonic aciduria
title_full_unstemmed Clinical experience with N-carbamylglutamate in a single-centre cohort of patients with propionic and methylmalonic aciduria
title_short Clinical experience with N-carbamylglutamate in a single-centre cohort of patients with propionic and methylmalonic aciduria
title_sort clinical experience with n-carbamylglutamate in a single-centre cohort of patients with propionic and methylmalonic aciduria
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949587/
https://www.ncbi.nlm.nih.gov/pubmed/27489777
http://dx.doi.org/10.1016/j.ymgmr.2016.06.007
work_keys_str_mv AT burlinaalberto clinicalexperiencewithncarbamylglutamateinasinglecentrecohortofpatientswithpropionicandmethylmalonicaciduria
AT cazzorlachiara clinicalexperiencewithncarbamylglutamateinasinglecentrecohortofpatientswithpropionicandmethylmalonicaciduria
AT zanonatoelisa clinicalexperiencewithncarbamylglutamateinasinglecentrecohortofpatientswithpropionicandmethylmalonicaciduria
AT viggianoemanuela clinicalexperiencewithncarbamylglutamateinasinglecentrecohortofpatientswithpropionicandmethylmalonicaciduria
AT fasanilaria clinicalexperiencewithncarbamylglutamateinasinglecentrecohortofpatientswithpropionicandmethylmalonicaciduria
AT pologiulia clinicalexperiencewithncarbamylglutamateinasinglecentrecohortofpatientswithpropionicandmethylmalonicaciduria